Runjhun Jain earnings call questions

Gland Pharma Limited CC-Mar25.pdf · 2025-05-20

Thank you everyone for joining us today. We truly appreciate your insightful questions and engagement throughout this session. Should any further questions arise, please GLAND Gland Pharma LimitedMay 20, 2025the existing products have made as far as the volume growth is concerned, as well asthe new launchers, and how the pricing have behaved?Shyamakant Giri:Yes, so Vivek, as I told you, if we in the US, FY'25, the volume growth has been plus9%, the price has been minus 5%. On the new product front, for the full year, the newlaunches in the US contributed 6% of the overall revenue. The new product’s grossmargin is 72% for the full year. So yes, these are data that is around the US.Vivek Agarwal:Understood. And for the next year, you are giving a kind of mid-teen kind of growthat the consolidated level. But how to look at growth in the US, because I think youneed to file in the US in order to achieve that kind of growth that is what myunderstanding is. Or, for example, it is the other markets you are thinking of filing?Thank you.Shyamakant Giri:So, if you see, Vivek, in the US market, our top 10 molecule revenue grew by 26%.You know, so we are really preserving our top business in many ways. And becausegrowth is a function of new launches, new approvals that will come on average, welaunched 33 products this year and we intend to continue that momentum in the comingyear. So, it will be a combination of new customer acquisition, and it will be acombination of new customer acquisition plus value expansion with new ANDAs andall of that with existing customers.Srinivas Sadu:So, US, the estimate is next year, 18%, 12% of the products and 6% from the CMOprojects to the US. So, it's about 18% expected.Vivek Agarwal:And lastly, actually, if you can answer, going into front end in the US, so is it still thereon the platter or the plan has been dropped?Srinivas Sadu:Still evaluating, I mean, like you said, everybody is paused. So we are looking at howthis tariff thing works out and how it's going to impact and all that. But it's not out ofthe data yet. We are still looking at it.Moderator:Ladies and gentlemen, we will take that as the last question. I will now hand theconference over to Ms. Runjhun Jain for closing comments.Runjhun Jain:Thank you everyone for joining us today. We truly appreciate your insightful questionsand engagement throughout this session. Should any further questions arise, please don't hesitate to reach us. We look forward to connecting with you again next quarter. Thank you.